ALG1

Chitobiosyldiphosphodolichol beta-mannosyltransferase

0 patent compounds predicted against ALG1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Germline variants in ALG1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ALG1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ALG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
High Dose or High Dose Frequency Study of Alglucosidase Alfa	PHASE4	COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease	PHASE3	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers	PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Efficacy of Intravaginal Carboxymethyl-β-glucan and Polycarbophil on Low-grade Cervical Lesions (GLUCANCIN)	nan	UNKNOWN
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease	nan	WITHDRAWN
Longitudinal Studies of the Glycoproteinoses	nan	COMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
A Natural History Study of the Gangliosidoses	nan	RECRUITING
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease	nan	APPROVED_FOR_MARKETING
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing	nan	UNKNOWN
Characterization of the Patient Population With Galactosialidosis	nan	COMPLETED
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease	nan	NO_LONGER_AVAILABLE
The Natural History of Sialidosis Type I	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ALG1 binder may also engage these)

Protein	Name	Similarity
Q5R7A2	—	1.000	Q5R7A2 →
Q921Q3	—	1.000	Q921Q3 →
Q8L7M0	—	0.979	Q8L7M0 →
Q9D0Z3	—	0.975	Q9D0Z3 →
Q7ZW24	—	0.973	Q7ZW24 →
LPCAT1	Lysophosphatidylcholine acyltransferase 1	0.972	landscape →
Q4V9J0	—	0.971	Q4V9J0 →
Q2TAA5	—	0.971	Q2TAA5 →
Q1HAQ0	—	0.970	Q1HAQ0 →
Q5R7Z6	—	0.969	Q5R7Z6 →
Q3TFD2	—	0.969	Q3TFD2 →
Q5NVK5	—	0.969	Q5NVK5 →
Q2TBP5	—	0.968	Q2TBP5 →
A5PK19	—	0.968	A5PK19 →
Q64323	—	0.968	Q64323 →
Q3TZM9	—	0.967	Q3TZM9 →
Q08B22	—	0.967	Q08B22 →
Q5EA80	—	0.966	Q5EA80 →
Q148G5	—	0.966	Q148G5 →
Q9XEE9	—	0.966	Q9XEE9 →
F4ZGF2	—	0.965	F4ZGF2 →
A5A779	—	0.965	A5A779 →
Q8N6R0	—	0.965	Q8N6R0 →
Q9JLV6	—	0.965	Q9JLV6 →
Q14CH1	—	0.965	Q14CH1 →
P22734	—	0.965	P22734 →
Q922Z0	—	0.965	Q922Z0 →
Q91YR5	—	0.965	Q91YR5 →
O43272	—	0.964	O43272 →
Q5I0L3	—	0.964	Q5I0L3 →